<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 03, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00002667</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000064256</org_study_id>
    <secondary_id>E-5593</secondary_id>
    <secondary_id>SWOG-9437</secondary_id>
    <secondary_id>JHOC-9152</secondary_id>
    <secondary_id>NCI-P95-0067</secondary_id>
    <nct_id>NCT00002667</nct_id>
  </id_info>
  <brief_title>Early Detection of Second Lung Cancer in Patients With Stage I Non-small Cell Lung Cancer</brief_title>
  <official_title>EARLY DETECTION OF SECOND PRIMARY LUNG CANCERS BY SPUTUM CYTOLOGY IMMUNOSTAINING</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Eastern Cooperative Oncology Group</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>Southwest Oncology Group</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Eastern Cooperative Oncology Group</source>
  <brief_summary>
    <textblock>
      RATIONALE: Using new methods to examine sputum samples for the presence of cancer cells may&#xD;
      detect lung cancer earlier.&#xD;
&#xD;
      PURPOSE: Screening trial to study the effectiveness of new methods of examining sputum&#xD;
      samples to detect second primary lung cancer in patients with resected stage I non-small cell&#xD;
      lung cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES: I. Evaluate whether immunostaining of induced sputum specimens improves the&#xD;
      sensitivity and specificity of routine morphologic sputum surveillance to detect second&#xD;
      primary lung cancer in patients with previously resected nonsmall cell lung cancer. II.&#xD;
      Evaluate which patients are at risk of developing a second primary lung cancer by&#xD;
      immunostaining specimens from patients with no morphologic atypia on routine Papanicolaou&#xD;
      cytology. III. Make available archived sputum samples and bronchial washings for further&#xD;
      analysis of new antibodies and techniques. IV. Evaluate whether analysis of elevations of&#xD;
      relevant growth factors in bronchial lavage fluid from patients with positive immunostaining&#xD;
      or morphologic atypia increases the accuracy of early detection. V. Evaluate whether&#xD;
      quantitation of shed antigens in sputum increases the accuracy of early detection. VI.&#xD;
      Evaluate whether the extent of airway obstruction, as measured by the forced expiratory&#xD;
      volume, can predict an increased risk of developing lung cancer.&#xD;
&#xD;
      OUTLINE: Screening for Second Primary Lung Cancer. Annual sputum induction for Papanicolaou&#xD;
      cytology and immunostaining (using monoclonal antibodies 624H12 and 703D4), with optional&#xD;
      pulmonary function tests and fiberoptic bronchoscopy with bronchial washings.&#xD;
&#xD;
      PROJECTED ACCRUAL: 1,100 patients will be entered over 3 years. The sample size will be&#xD;
      adjusted based on the rate of positive staining in the first 100 patients. Patients followed&#xD;
      at uncertified centers are analyzed separately.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">July 1995</start_date>
  <completion_date type="Actual">October 1, 2004</completion_date>
  <primary_completion_date type="Actual">October 1, 2004</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Screening</primary_purpose>
  </study_design_info>
  <enrollment type="Anticipated">1100</enrollment>
  <condition>Lung Cancer</condition>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>cytology specimen collection procedure</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>immunoenzyme technique</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>study of high risk factors</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS: Stage I (T1-2 N0) nonsmall cell lung cancer curatively resected&#xD;
        and in regular follow-up for at least 6 weeks Material available for histologic review At&#xD;
        least 1 mediastinal node station sampled or at least 2 years since surgery Any of the&#xD;
        following histologies eligible: Squamous cell carcinoma Large cell carcinoma Adenocarcinoma&#xD;
        (including bronchoalveolar) No small cell anaplastic component No recurrent disease or&#xD;
        second primary No synchronous lung cancer of a different histology Concurrent registration&#xD;
        on intergroup protocol I91-0001 allowed&#xD;
&#xD;
        PATIENT CHARACTERISTICS: Age: 18 and over Performance status: Not specified Cardiovascular:&#xD;
        No history of severe hypertension, i.e.: Systolic 200 mm Hg or more Diastolic 120 mm Hg or&#xD;
        more No MI within 6 weeks Pulmonary: Available for annual sputum induction and clinical&#xD;
        evaluation Clinically able to undergo pulmonary function tests (PFTs) and bronchoscopy&#xD;
        Refusal of PFTs or bronchoscopy will not effect eligibility PFTs waived if FEV1/FVC &lt; 65%&#xD;
        on prior testing No acute respiratory infection Other: No prior uncontrolled malignancy&#xD;
        except nonmelanomatous skin cancer Exceptions for malignancy controlled more than 5 years&#xD;
        discretionary&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY: Complete surgical resection required as primary therapy At least&#xD;
        6 weeks since resection, any adjuvant chemotherapy or radiotherapy, or thoracoabdominal&#xD;
        surgery&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>120 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>John C. Ruckdeschel, MD</last_name>
    <role>Study Chair</role>
    <affiliation>H. Lee Moffitt Cancer Center and Research Institute</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Paul A. Bunn, MD</last_name>
    <role>Study Chair</role>
    <affiliation>University of Colorado, Denver</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>H. Lee Moffitt Cancer Center and Research Institute</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33612</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CCOP - Iowa Oncology Research Association</name>
      <address>
        <city>Des Moines</city>
        <state>Iowa</state>
        <zip>10309-1016</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CCOP - Northern New Jersey</name>
      <address>
        <city>Hackensack</city>
        <state>New Jersey</state>
        <zip>07601</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ireland Cancer Center</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44106-5065</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Allegheny University Hospitals- Hahnemann</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19102-1192</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2022</verification_date>
  <study_first_submitted>November 1, 1999</study_first_submitted>
  <study_first_submitted_qc>July 16, 2004</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 19, 2004</study_first_posted>
  <last_update_submitted>June 8, 2022</last_update_submitted>
  <last_update_submitted_qc>June 8, 2022</last_update_submitted_qc>
  <last_update_posted type="Actual">June 9, 2022</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>stage I non-small cell lung cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

